Skip to content
HowShorted

Clovis Oncology, Inc. short interest in 2021

In 2021, Clovis Oncology, Inc.'s disclosed short interest ran from 40.89% of shares outstanding on 15 Jan 2021 to 19.02% on 31 Dec 2021, a change of -21.87 percentage points. The year's high was 40.89% on 15 Jan 2021 and its low 19.02% on 31 Dec 2021, averaging 27.01% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 12.90 days on 15 Oct 2021. Full history: Clovis Oncology, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022

Aggregate net short position time series for Clovis Oncology, Inc. in 2021

2021 in figures

Start of year
40.89% (15 Jan 2021)
End of year
19.02% (31 Dec 2021)
Change
-21.87 pp
High
40.89% (15 Jan 2021)
Low
19.02% (31 Dec 2021)
Average
27.01%
Highest days to cover
12.90 (15 Oct 2021)
SEC filings marked
9

Every report in 2021

Clovis Oncology, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202140.89%7.97results (8-K)
29 Jan 202140.86%2.89
12 Feb 202131.59%3.60
26 Feb 202134.63%4.24results (8-K), 10-K filed
15 Mar 202133.00%5.28
31 Mar 202130.84%1.00
15 Apr 202130.29%8.73
30 Apr 202129.13%10.56
14 May 202130.06%6.9010-Q filed, results (8-K)
28 May 202129.47%8.48
15 Jun 202127.40%2.50
30 Jun 202126.01%4.64
15 Jul 202127.08%4.60
30 Jul 202124.93%9.84
13 Aug 202123.54%10.1610-Q filed, results (8-K)
31 Aug 202122.95%8.92
15 Sep 202121.14%7.18
30 Sep 202122.48%8.50
15 Oct 202121.47%12.90
29 Oct 202120.46%12.30
15 Nov 202120.36%7.9010-Q filed, results (8-K)
30 Nov 202120.37%5.97
15 Dec 202120.16%6.12
31 Dec 202119.02%6.55

See also: Clovis Oncology, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.